Pharmigene (ROCO:7595) Debt-to-Equity : 1.29 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Pharmigene Debt-to-Equity?

Pharmigene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$6.5 Mil. Pharmigene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$564.6 Mil. Pharmigene's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$444.1 Mil. Pharmigene's debt to equity for the quarter that ended in Dec. 2023 was 1.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharmigene's Debt-to-Equity or its related term are showing as below:

ROCO:7595' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.05 Max: 1.29
Current: 1.29

During the past 7 years, the highest Debt-to-Equity Ratio of Pharmigene was 1.29. The lowest was 0.03. And the median was 0.05.

ROCO:7595's Debt-to-Equity is ranked worse than
90.16% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs ROCO:7595: 1.29

Pharmigene Debt-to-Equity Historical Data

The historical data trend for Pharmigene's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmigene Debt-to-Equity Chart

Pharmigene Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.05

0.04

0.03

1.29

Pharmigene Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial							0.04	0.04	0.03	1.74	1.29

Competitive Comparison of Pharmigene's Debt-to-Equity

For the Diagnostics & Research subindustry, Pharmigene's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmigene's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharmigene's Debt-to-Equity falls into.

Pharmigene Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharmigene's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.534	+	564.562)	/	444.101
	=	1.29

Pharmigene's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.534	+	564.562)	/	444.101
	=	1.29

Pharmigene (ROCO:7595) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharmigene Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharmigene's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmigene (ROCO:7595) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pharmigene Inc (ROCO:7595) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 101 Ruihu Street, 5th Floor, Neihu District, Taipei, TWN, 11494

Website

https://www.pharmigene.com

Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.

Pharmigene (ROCO:7595) Headlines

No Headlines